Letrozole Oral
Femara 2.5 mg contains letrozole, a third-generation non-steroidal aromatase inhibitor. Letrozole works by reversibly binding to the aromatase enzyme, which is responsible for converting androgens into estrogens. By inhibiting this conversion, letrozole significantly reduces circulating estrogen levels in the body.
In medical practice, letrozole is indicated for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, as well as first and second-line treatment of advanced breast cancer in postmenopausal women. It is not approved for use in men or for bodybuilding purposes. In non-medical bodybuilding contexts, letrozole is commonly referenced as a potent aromatase inhibitor for managing estrogen-related side effects during cycles involving aromatizable compounds.
Letrozole is considered one of the most potent aromatase inhibitors available, capable of suppressing estrogen levels by 75% to 95% from baseline. This potency makes it a subject of discussion in bodybuilding circles, though its use in this context falls outside approved medical indications. The 2.5 mg strength is the standard clinical dose, and bodybuilding references typically suggest significantly lower doses to avoid excessive estrogen suppression.
Key Benefits of Femara 2.5 mg
- Potent non-steroidal aromatase inhibitor for estrogen management
- Significantly suppresses circulating estrogen levels
- Oral tablet format for convenient administration
- Commonly referenced in bodybuilding contexts for cycle support
- 2.5 mg strength allows for dose splitting when lower doses are desired
Non-Steroidal Aromatase Inhibitor
Letrozole belongs to the aromatase inhibitor class of compounds, specifically the third-generation non-steroidal subtype. Unlike steroidal aromatase inhibitors such as exemestane, which irreversibly bind to the aromatase enzyme, letrozole acts as a reversible competitive inhibitor. This means it blocks the enzyme's activity while present but does not permanently deactivate it.
The aromatase enzyme catalyzes the conversion of androgens such as testosterone and androstenedione into estrogens. By inhibiting this enzyme, letrozole reduces the production of estrogen in peripheral tissues. In clinical studies, daily doses of letrozole from 0.1 mg to 5 mg suppressed plasma concentrations of estradiol, estrone, and estrone sulfate by 75% to 95% from baseline.
Letrozole has a terminal elimination half-life of approximately 2 days. Steady-state plasma concentrations are reached in 2 to 6 weeks with daily dosing of 2.5 mg. The compound is rapidly and completely absorbed from the gastrointestinal tract, with absorption not affected by food.
Potency
Potent Estrogen Suppression
Letrozole is recognized as one of the most potent aromatase inhibitors available. Clinical data demonstrates suppression of estradiol, estrone, and estrone sulfate by 75% to 95% from baseline at doses ranging from 0.1 mg to 5 mg daily.
Femara 2.5 mg vs Other Dragon Pharma Preparations
Dragon Pharma offers a range of compounds relevant to hormonal management during cycles. Femara 2.5 mg is positioned as a potent aromatase inhibitor, complementing other ancillary products.
For alternative estrogen management, Dragon Pharma offers Arimidex and Aromasin, which are also aromatase inhibitors but with different potency profiles and mechanisms of action. For prolactin management, Caber is commonly referenced in conjunction with 19-nor compounds.
Typical Dosage Ranges
In medical practice, the recommended dose of letrozole is one 2.5 mg tablet administered once daily, without regard to meals. In non-medical bodybuilding contexts, letrozole is commonly referenced at significantly lower doses due to its potency. A forum analysis of aromatase inhibitor use among steroid users reported a mean letrozole dose of 2 mg per day. However, many bodybuilding references suggest starting at 0.25–0.625 mg daily or every other day to avoid excessive estrogen suppression.
| Use Case |
Common Reference Range |
Frequency |
| Medical (breast cancer) |
2.5 mg |
Once daily |
| Bodybuilding (non-medical) |
0.25–1 mg |
Daily or EOD |
| Cycle support (aggressive) |
1.25–2.5 mg |
Daily or as needed |
Femara 2.5 mg tablets may require splitting to achieve the lower doses commonly referenced in non-medical contexts.
Stacking & Cycle Considerations
Letrozole is not an anabolic compound and is not stacked for muscle-building purposes. It is used as a support ancillary in cycles where estrogen management is a concern, most commonly those involving aromatizable compounds such as testosterone. In non-medical contexts, letrozole is often reserved for situations where other aromatase inhibitors have proven insufficient, given its potency.
Dragon Pharma offers Arimidex and Aromasin as alternative aromatase inhibitors with different potency profiles. The choice between these agents depends on individual response and the degree of estrogen suppression desired.
Managing Side Effects
Letrozole's potent estrogen suppression can lead to side effects associated with low estrogen, including joint pain, mood changes, and decreased libido. In clinical trials, arthralgia was reported in 25.2% of patients taking letrozole compared to 20.4% taking tamoxifen. Bone fractures were also more common with letrozole (10.1% vs 7.1%). These effects are related to estrogen's role in maintaining bone density and joint health.
Because letrozole is so effective at suppressing estrogen, it is generally not recommended as a first-line aromatase inhibitor in non-medical bodybuilding contexts. Starting with lower doses and monitoring for signs of excessive estrogen suppression can help mitigate these effects.
Post-Cycle Therapy
Letrozole is not typically part of standard post-cycle therapy protocols, which focus on restoring endogenous testosterone production. PCT compounds such as Clomid and Nolvadex address the hypothalamic-pituitary-gonadal axis rather than estrogen synthesis. Letrozole's role is generally limited to on-cycle estrogen management.
Important
Individual Response Varies
Dosing strategies and support protocols should be adjusted based on experience level and bloodwork where possible. The information above is for educational reference and does not constitute medical advice.
Important Safety Information
Letrozole is indicated for the treatment of postmenopausal women with hormone receptor-positive breast cancer. It is not approved for use in men or for bodybuilding purposes. Clinical evaluation before initiation typically includes assessment of bone health and lipid parameters.
Important
Non-Medical Use
Non-medical use of letrozole for estrogen management during performance-enhancement cycles is not approved by regulatory agencies and may carry additional health risks. Product quality does not establish that non-medical use is safe or appropriate.
Potential Adverse Effects
Letrozole has been associated with significant bone loss. A safety trial comparing letrozole to tamoxifen in postmenopausal women showed a median decrease in lumbar spine bone mineral density of 4.1% at 24 months in the letrozole arm, compared to a median increase of 0.3% in the tamoxifen arm. This reflects the importance of estrogen in maintaining bone density.
Other adverse effects reported in clinical trials include arthralgia (25.2%), hot flashes, hypercholesterolemia, and increased fracture risk (10.1% vs 7.1% for tamoxifen). Cardiovascular events, including myocardial infarctions, were also more common with letrozole (1.0% vs 0.5%).
Letrozole may impair fertility in both males and females based on animal studies. It can cause fetal harm when administered to a pregnant woman.
Conditions Requiring Medical Evaluation
Letrozole should be used with caution in individuals with hepatic impairment. In patients with severe hepatic impairment (Child-Pugh class C), exposure to letrozole is approximately doubled, and the recommended dose should be reduced by 50%. Pre-existing bone disease, osteoporosis, or risk factors for fractures should be evaluated before use.
Monitoring During Therapy
Medically supervised letrozole therapy typically involves periodic monitoring of bone mineral density and lipid profiles. In clinical settings, patients receiving aromatase inhibitors may be supplemented with calcium and vitamin D, and bone density may be assessed at baseline and annually. Laboratory testing of the product itself is separate from clinical monitoring of the individual.
Product Care
Storage & Handling
Keep the product securely stored and protected from conditions that could compromise the tablets or packaging. Inspect the product before use and do not use if it appears damaged or otherwise abnormal. Keep all medications out of the reach of children.
Further Safety Information
USA Domestic 3–5 business days
International 10–15 business days
Order Processing 24–48 business hours
Tracking Provided after dispatch
Direct Supply
Discreet Delivery & Original Packaging
The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details. Products are supplied through the official Dragon Pharma distribution chain.
What to Expect
- Orders are processed after payment confirmation
- USA Domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity Verification
To verify your Femara 2.5 mg product, use the security code on the packaging and cross-check it on the Dragon Pharma official site. Official Dragon Pharma presentation and original packaging help reinforce product legitimacy and buyer confidence.
Recommended Conditions
Store in a cool, dry place at controlled room temperature (15–25°C). Protect from excessive heat, moisture, and direct light. Keep the tablets in their original packaging until use.
Do not use if the packaging appears damaged or if the tablets show signs of deterioration. Keep out of reach of children.
Quick Reference
Do & Don't
- Do store at 15–25°C
- Do keep in original packaging
- Do inspect before use
- Don't expose to excessive heat
- Don't store in humid environments
- Don't use if packaging is compromised
What is Femara 2.5 mg used for?
Femara 2.5 mg contains letrozole, an aromatase inhibitor. In medical practice it is used for the treatment of hormone receptor-positive breast cancer in postmenopausal women. In non-medical bodybuilding contexts, it is commonly referenced for managing estrogen-related side effects during cycles involving aromatizable compounds. Such use falls outside approved medical indications.
How often should Femara 2.5 mg be taken?
In medical practice, the recommended dose is 2.5 mg once daily. In non-medical bodybuilding contexts, letrozole is commonly referenced at lower doses, often 0.25–1 mg daily or every other day, due to its potency. A forum analysis reported a mean dose of 2 mg per day among users, but many references suggest starting lower to avoid excessive estrogen suppression.
Does Femara 2.5 mg require PCT?
Letrozole is not part of standard post-cycle therapy, which focuses on restoring endogenous testosterone production. PCT compounds like Clomid and Nolvadex address the hypothalamic-pituitary-gonadal axis rather than estrogen synthesis. Letrozole's role is generally limited to on-cycle estrogen management.
What does letrozole do?
Letrozole inhibits the aromatase enzyme, which converts androgens into estrogens. This reduces circulating estrogen levels by 75% to 95% from baseline. In medical contexts, this is used to treat hormone-sensitive breast cancer. In non-medical bodybuilding contexts, this mechanism is used to manage estrogen-related side effects during cycles.
How long does letrozole take to work?
Letrozole has a terminal elimination half-life of approximately 2 days. Steady-state plasma concentrations are reached in 2 to 6 weeks with daily dosing. Maximal estrogen suppression is typically achieved within 2 to 3 days of initiating treatment.
Is letrozole the best aromatase inhibitor?
There is no single aromatase inhibitor that is universally best. Letrozole is considered one of the most potent, but this potency also means it carries a higher risk of excessive estrogen suppression and associated side effects. Other options like Arimidex and Aromasin are commonly referenced, with different potency profiles and mechanisms of action.
What is the difference between letrozole and Arimidex?
Letrozole and Arimidex (anastrozole) are both non-steroidal aromatase inhibitors, but letrozole is generally considered more potent. Letrozole suppresses estrogen by 75% to 95%, while anastrozole has a somewhat milder effect. This difference in potency is a key consideration in both clinical and non-medical contexts.
What is the difference between letrozole and Aromasin?
Letrozole and Aromasin (exemestane) are both aromatase inhibitors but work differently. Letrozole is a reversible non-steroidal inhibitor, while exemestane is an irreversible steroidal inhibitor. Exemestane may cause fewer skeletal and lipid-related adverse effects compared to letrozole.
Is 2.5 mg of letrozole a lot?
In medical practice, 2.5 mg daily is the standard dose for breast cancer treatment. In non-medical bodybuilding contexts, 2.5 mg is considered a high dose due to letrozole's potency, and lower doses are commonly referenced. The 2.5 mg strength of Femara 2.5 mg allows for splitting to achieve these lower doses.
What strength is Femara 2.5 mg?
Femara 2.5 mg is labeled at 2.5 mg of letrozole per tablet. It is supplied in a 100-tablet package, giving 250 mg of total labeled letrozole content.
Does letrozole affect bone density?
Yes. Letrozole has been associated with significant bone loss due to its suppression of estrogen, which is important for bone health. A clinical trial showed a median decrease in lumbar spine bone mineral density of 4.1% at 24 months in patients taking letrozole. Fractures were also more common with letrozole compared to tamoxifen.
No reviews found
Please log in to write Femara 2.5 mg review.
